课题基金 / 基金详情

Type II: University of Utah Center for Medical Innovation I-Corps Site

Type II: University of Utah Center for Medical Innovation I-Corps Site
II 类:犹他大学医学创新中心 I-Corps 网站
批准号:
1735781
负责人:
John Langell
金额:
$29.78万
依托单位:
依托单位国家:
美国
项目类别:
Continuing Grant
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-08-01 至 2023-07-31

项目摘要

项目成果

John Langell的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This project, from the University of Utah, creates an I-Corps Site at this institution.NSF Innovation Corps (I-Corps) Sites are NSF-funded entities established at universities whose purpose is to nurture and support multiple, local teams to transition their technology concepts into the marketplace. Sites provide infrastructure, advice, resources, networking opportunities, training and modest funding to enable groups to transition their work into the marketplace or into becoming I-Corps Team applicants. I-Corps Sites also strengthen innovation locally and regionally and contribute to the National Innovation Network of mentors, researchers, entrepreneurs and investors.This is a Type II proposal, requesting a "renewal" of funding for an existing I-Corps Site. There are two types of I-Corps Site proposals. Type I proposals are submitted by institutions that have not had prior funding as an I-Corps Site. These proposals may request $100,000 per year for up to five years. Type II proposals are submitted by institutions that have had prior funding as an I-Corps Site. These proposals may request up to $100,000 per year for up to three years.The University of Utah I-Corps Site program encourages and assists students and faculty in transitioning research projects to commercialization by providing education, training, resources and networking required for understanding markets, customers, product-market fit and to answer business and/or technology questions. The I-Corps Site program at the University of Utah is currently in its 3rd year and has trained nearly 90 teams and over 150 participants. The program resulted in successful business and technology go/no-go decisions, successful transition to commercialization, and helped advance five technologies to the commercial start-up stage. This extension focuses on refining the curriculum by implementing lessons learned in the first three years of the program, developing new teams and generating more successful transitions, as well as implementing the new financing model that will assure future program sustainability without further government funding.The Utah I-Corps Site enhances and builds upon this institution's existing expertise in medical device innovation, commercialization and entrepreneurship. This Site initiated the development of a model of transitioning from research-based technologies to viable commercial products in academic environment that allows the university to expand their innovation programs, provide more impactful resources to faculty and student innovation teams and improve recruitment of underrepresented participants. This extension further generalizes and disseminates the developed curriculum and implements agreements and procedures to assure its future financial sustainability. Partnership networks within the university support underrepresented student and faculty groups and offer the support and resources needed to help such groups thrive and participate in the process and, as the program becomes self-sustaining, will be extended, through internships and special courses to other colleges and local high schools. Thus, the program helps increase the diversity of the regional business environment leading to enhanced growth and economic prosperity for all citizens in the region.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
University of Utah Center for Medical Innovation I-Corp Site
  • 批准号:
    1347345
  • 项目类别:
    Continuing Grant
  • 资助金额:
    $30.0万
  • 财政年份:
    2014
  • 负责人:
    John Langell
  • 依托单位:
国内基金
海外基金
基于生境成像与深度学习联合临床特征构建II型卵巢癌术前淋巴结转移预测模型的研究
青蒿琥酯协同TROP2/线粒体级联靶向的NIR-II多模态诊疗用于晚期TNBC精准诊断与治疗的机制研究
  • 批准号:
    2026JJ30126
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    杨沙
  • 依托单位:
鸡软骨非变性II型胶原高效制备和靶向递送的关键技术开发与应用示范
苏合颗粒治疗慢性萎缩性胃炎的临床(II期)评价关键技术研究